



Contact:  
Bill Enright  
President & CEO  
Phone: 205-909-3751  
Email: enright@vaxin.com

## VAXIN WELCOMES NEW CEO

### *New Leader To Advance Company's Product Pipeline Into Clinical Development*

**Birmingham, Alabama** --August 4, 2008-- As Vaxin has advanced its groundbreaking, needle-free vaccine candidates, the need has grown for additional depth in its executive ranks. The company has addressed that growing need by naming William "Bill" Enright as its new President and Chief Executive Officer. Mr. Enright will be focused on moving Vaxin's influenza vaccines, both pandemic (H5N1) and seasonal, into human clinical testing and leading efforts for financing these initiatives.

Mr. Enright joined Vaxin in June following six years with GenVec, Inc., where he most recently served as the Head of Business Development, working to build GenVec's vaccine business. Part of his success there included leading efforts to bring approximately \$140M in funding for vaccine related programs and successfully advancing four vaccine candidates into clinical development.

"We are very pleased to bring Bill on board as our new CEO," said Kent Van Kampen, who will remain as Vaxin's Chief Operating Officer. "His twenty years of experience within the life science/biotech industry and extensive contacts will be a valuable addition to our team."

"Joining Vaxin presents me with a unique opportunity to bring an exciting new technology out of the lab and into the market," said Mr. Enright. He added, "Vaxin's single-dose, needle-free molecular vaccines have the potential to change the vaccine industry."

After beginning his life sciences career as a bench scientist at SUNY at Buffalo, where he earned a Master of Arts degree in Molecular Biology, Mr. Enright spent 12 years with Life Technologies, Inc. (now part of Invitrogen). While at LTI/Invitrogen he held various licensing, business management, manufacturing and research roles.

Mr. Enright's career also includes time working as an industry consultant, providing business development and strategic marketing services to academic institutions and numerous life science companies. He also holds a Master of Science in Business Management from Johns Hopkins University, and has extensive experience serving on various committees at the National Institutes of Health.

### About Vaxin:

Vaxin Inc. is an emerging vaccine company with a lead in the development of needle-free, single dose highly effective vaccines. These molecular vaccines are safely administered either in the nose or on the skin, taking the battle against diseases to the immune system's front lines where the diseases are attacking, rather than injecting the vaccine inside the body where the body's immune response is actually weaker. This also allows Vaxin's vaccines to be mass administered by personnel without sophisticated medical training.

As a vaccine delayed may be a vaccine denied, it is crucial to produce vaccines in a timely manner, especially in the event of a pandemic or bioterrorist attack. The company's technology platform also provides a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer's disease utilizing molecular techniques and state of the art cell culture based manufacturing. Vaxin's vaccines are not dependent on chicken eggs and can therefore be more reliably produced even in the event of avian epidemics.

Vaxin's unique technology was developed by Dr. De-chu C. Tang, Vaxin's scientific founder and Vice President of Research. Unlike current vaccines, which typically use a weakened form of the targeted disease, such as the influenza virus, Vaxin's molecular vaccines are created by inserting only a piece of the influenza virus, the antigen, into a benign delivery vehicle. This "Trojan Horse" method increases the safety of the vaccine and virtually eliminates the risk of a vaccine reverting to a disease causing agent.

Needle-free, non-replicating, single-dose molecular vaccines also have many other advantages. Patients clearly prefer vaccines which are not injected because there is no fear of needles or the pain they can cause.

Vaxin's technology also has applications for animal health uses. Automated *in ovo* (in the egg) vaccination is the method of choice for the mass immunization of poultry because of the ease of administration and lower costs. Unlike most technologies that have been tried, Vaxin's technology provides the ability to administer a protective vaccine *in ovo* without harming the embryo.

### Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

# # #